Corvus Pharmaceuticals (CRVS) Total Liabilities (2015 - 2026)

Corvus Pharmaceuticals' Total Liabilities history runs 12 years deep, the most recent figure standing at $12.5 million for Q1 2026.

• In Q1 2026, Total Liabilities rose 23.76% year-over-year to $12.5 million; the TTM figure through Mar 2026 stood at $12.5 million (up 23.76% YoY), while the FY2025 annual figure was $9.9 million, down 72.72% from the prior year.
• Total Liabilities was $12.5 million for Q1 2026 at Corvus Pharmaceuticals, up from $9.9 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $46.4 million in Q3 2024 to a low of $6.7 million in Q1 2024.
• Historically, Total Liabilities has averaged $14.0 million across 5 years, with a median of $10.1 million in 2025.
• The sharpest annual moves came in 2024 and 2025: Total Liabilities soared 506.38% in 2024, then slumped 81.24% in 2025.
• A 5-year view of Total Liabilities shows it stood at $12.1 million in 2022, then tumbled by 43.35% to $6.9 million in 2023, then soared by 429.03% to $36.3 million in 2024, then slumped by 72.72% to $9.9 million in 2025, then rose by 26.25% to $12.5 million in 2026.
• The last three Total Liabilities figures came in at $12.5 million (Q1 2026), $9.9 million (Q4 2025), and $8.7 million (Q3 2025), per Business Quant data.